Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GERN
GERON CORPORATION
NASDAQ
$1.51
▼ DOWN 1.31% (-0.02)

KEY STATISTICS

Market Cap$968.70 M
52w High$2.01
52w Low$1.04
Dividend Yield—
Frequency—
P/E-16.78
Volume7.33M
Shares Out.641.52M

COMPANY

LEADERSHIP

Harout Semerjian
CHIEF EXECUTIVE
Harout Semerjian

COMPENSATION 2026

Salary$318,190
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$40,258
Total$522,122

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 31, 1996
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
258

PRICE TARGET

Target High$8.00
Target Low$4.00
Target Median$6.00
Target Consensus$5.89

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$60.70M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2014-07-22Forward529:500

PRICE

$1.51 ▼ DOWN 1.31% (−$0.02)
OVERLAYS
$1.50$1.51$1.52$1.539:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.51

About Geron Corporation

https://www.geron.com ↗

Geron Corporation is a late-stage biopharmaceutical company developing imetelstat, a telomerase inhibitor in Phase 3 trials for treating myeloid hematologic malignancies like myelodysplastic syndromes and myelofibrosis.

INDUSTRY

Biotechnology

A PRODUCT GERON CORPORATION IS KNOWN FOR

RYTELO (imetelstat)
RYTELO (imetelstat)

RYTELO, Geron's first FDA-approved telomerase inhibitor for transfusion-dependent lower-risk MDS, is their flagship product marking a milestone in hematologic malignancy treatment.

COMPETITORS

COMPETITOR
AGIO COMPARE
BMY COMPARE
INCY COMPARE
SNDX COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Revenues Before Adjustments$60.19M $59.74M ▼$65.35M ▲$72.44M ▲
Product$47.17M $48.01M ▲$51.77M ▲$57.47M ▲
Sales Returns And Allowance-$1.79M $0 ▲-$1.59M ▼-$1.43M ▲
Government Rebates-$2.14M $65K ▲-$1.66M ▼-$1.97M ▼
Chargebacks— — -$8.16M -$9.19M ▼
Total Gross To Net Adjustments-$13.02M $0 ▲-$13.58M ▼-$14.96M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
124
LISTED HERE
20
RANKED BY POSITION SIZE
XBI
0.30% · 23.3M
VTI
0.00% · 20.4M
IWM
0.03% · 14.3M
XMWD.L
0.03% · 2.9M
SCHA
0.02% · 2.5M
BBP
1.63% · 1.3M
LABU
0.20% · 845.6K
SBIO
0.50% · 793.9K
PRFZ
0.04% · 746.6K
ISMD
0.24% · 532.8K
ONEQ
0.00% · 350.6K
RSSL
0.03% · 265.6K
GSSC
0.02% · 159.5K
WBIO.L
0.34% · 74.9K
ESSC
0.12% · 35.1K
BIB
0.03% · 22.9K
VETS
0.07% · 13.5K
TILT
0.00% · 3.6K
USFMDN.MX
0.00% · 2.4K
RESM
0.03% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.94%
HOLDERS
374
TOP 12 OF 374 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
63.8M sh · $95.02M
Blackrock, Inc.
47.3M sh · $70.51M
Blackrock Inc.
46.6M sh · $197.38M
Soleus Capital Management, L.P.
41.5M sh · $61.85M
Deep Track Capital, LP
41.1M sh · $56.3M
Vanguard Group Inc
35.7M sh · $47.07M
State Street Corp
30.5M sh · $45.44M
Vivo Capital, LLC
27.2M sh · $37.3M
Citadel Advisors LLC
21.6M sh · $32.15M
Goldman Sachs Group Inc
21.3M sh · $29.19M
Point72 Asset Management, L.P.
20.5M sh · $30.48M
Clearbridge Investments, LLC
19.6M sh · $29.23M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR
Spiegel Robert J.
Purchase · 6.1K shares
2026-06-30
★
DIRECTOR
Bir Dawn Carter
Purchase · 220.0K shares
2026-05-20
★
DIRECTOR
Molineaux Susan
Purchase · 220.0K shares
2026-05-20
★
DIRECTOR
McDonald John F
Purchase · 220.0K shares
2026-05-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
Needham BUY

SECTORS PEERS

PEERPRICE
VIR$10.83COMPARE
TYRA$24.94COMPARE
AVBP$30.17COMPARE
REPL$15.50COMPARE
SVRA$5.26COMPARE
VALN$6.43COMPARE
ARVN$9.18COMPARE
RZLT$4.62COMPARE